Gapping up
In reaction to strong earnings/guidance:
- HOME +12.2%, VERO +10.5%, NVTA +8.6%, SFET +6.1%, RIGL +5.8%, AXGN +5%, CALA +3.2%, CDNA +2.8%, CDLX +2.3%, LULU +2.2%, GWPH +1.6%, RRGB +1.5%, CROX +1.4%, SIEN +1.4%, AEO +1.3%, STAA +1.1%
M&A news:
- PRMW +26.4% (Cott Corporation (COT) will acquire PRMW for $14.00/share in cash)
- TERP +11% (confirms receipt of unsolicited proposal from Brookfield Renewable (BEP) and announces formation of special committee)
- OCX +9.4% (to acquire Insight Genetics for closing consideration of approx. $12 mln)
- JMEI +7.9% (receives non-binding proposal to be acquired for $20.0 per ADS)
- HXL +5.2% (Woodward (WWD) and Hexcel (HXL) combine in merger of equals)
- TDOC +2.3% (to acquire InTouch Health)
- WWD +1.8% (Woodward (WWD) and Hexcel (HXL) combine in merger of equals)
Other news:
- VRNA +58.4% (reports positive top-line data in 4 week Phase 2b COPD Study with nebulized ensifentrine on top of tiotropium therapy)
- ADAP +57.9% (reported two confirmed Partial Responses (PRs) -- one in a patient with liver cancer and one in a patient with melanoma)
- LCI +12.7% (announces FDA approval of nda for branded anesthetic product, cocaine hydrochloride nasal solution 4%)
- OBSV +7.6% (ObsEva and Yuyuan announce sublicense agreement to develop and commercialize nolasiban in the People's Republic of China)
- ADVM +7% (reports additional clinical data from first cohort of OPTIC Phase 1 trial of ADVM-022)
- DTIL +6.3% (FDA has accepted its IND application for PBCAR269A)
- KDMN +5.3% (indicated higher after late-breaking abstract of KD025 for cGVHD was accepted at the 2020 TCT Meetings)
- AXSM +5.3% (Axsome Therapeutics enters into exclusive license agreement with Pfizer (PFE) for Pfizer's Reboxetine clinical and nonclinical data and for new phase 3 esreboxetine product candidate)
- QTNT +4.6% (commences EU field trial activities and announces the FDA has received its 510(k) submission)
- CALA +3.2% (expects to utilize cash and investments $75-85 million in 2020)
- SNDX +2.1% (announces strategic outlook for 2020)
- LK +2% (upsizes offering and prices 13.8 mln shares of ADSs by co and selling shareholders at $42.00 per ADS)
- BHC +1.9% (publication of pivotal phase 3 data on Arazlo; Arazlo lotion demonstrated statistically significant superiority over placebo with favorable efficacy, safety and tolerability profile)
- MGI +1.8% (Moneygram and EbixCash (EBIX) sign exclusive strategic agreement to expand presence in India)
- ATRA +1.7% (presents new milestones for 2020)
Analyst comments:
- ERIC +2.3% (upgraded to Buy from Neutral at Citigroup)
- NVDA +1.5% (upgraded to Hold at Needham)
- INN +1.4% (upgraded to Overweight from Equal Weight at CapitalOne)
- AMT +0.9% (upgraded to Buy from Neutral at Goldman)
- GS +0.8% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)